(Page 2 of 2)
total funding for Fate is closer to $66 million.
—FDA regulators have cleared the mobile wireless technology that San Diego’s Sotera Wireless has developed for monitoring hospital patients’ vital signs. The FDA already approved Sotera’s ViSi mobile monitor, a device that wraps around a patient’s wrist and collects vital signs from sensors on the patient’s chest and thumb. The latest FDA decree clears the WiFi technology that Sotera uses to transmit the data to a hospital workstation.
—San Diego-based MediciNova said the Aspire Capital Fund made a $1 million investment as the first installment in an agreement to buy as much as $20 million worth of MediciNova shares over the next two years. MediciNova said it will use the proceeds to fund development of its lead drug candidates. One is for acute asthma and chronic obstructive pulmonary disease, and the other is targeting multiple sclerosis, drug addiction, and chronic pain.
—After reaching its first milestone, San Diego-based Aethlon Medical said the Pentagon’s Defense Advanced Research Projects Agency (DARPA) has agreed to continue funding the company’s work under an existing $6.8 million contract to advance dialysis-like therapies. Aethlon has been developing a device that uses antibody-coated filters to selectively filter infectious organisms, cancer cells, and other life-threatening particles in the bloodstream.